| Literature DB >> 30410549 |
Rajiva de Silva1, Dhanushka Dasanayake1, Manouri Senanayake2, Ramya Ediriweera2, Savithri Dias3, Chandima Karunatilleke1, Karen Brocas4, Fariba Tahami4, Suranjith Seneviratne4.
Abstract
BACKGROUND: Hyper IgE recurrent infection syndrome (HIES) is a rare immune deficiency, characterized by recurrent staphylococcal skin and lung abscesses, pneumonia and increased IgE levels. The majority of autosomal dominant HIES (AD HIGE) is due to hypomorphic mutations in the signal transducer and the activator of transcription 3 (STAT3) gene. CASEEntities:
Keywords: Autosomal dominant hyper IgE; Hyper IgE syndrome; Job’s syndrome; Primary immunodeficiency; STAT3 mutation
Year: 2018 PMID: 30410549 PMCID: PMC6214173 DOI: 10.1186/s13223-018-0292-3
Source DB: PubMed Journal: Allergy Asthma Clin Immunol ISSN: 1710-1484 Impact factor: 3.406
Fig. 1Patients with AD HIGE. a Patient 1, b patient 2, c skin manifestations of patient 2
Fig. 2Radiological manifestations of patient 1. a Chest X ray and b High-resolution computed tomography (HRCT) of chest
NIH Score based on [14]
| Feature | Score | ||||
|---|---|---|---|---|---|
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
| Highest serum IgE level | 10 | 10 | 10 | 10 | 10 |
| Skin abscess | 8 | 0 | 8 | 8 | 8 |
| Pneumonia | 8 | 0 | 0 | 6 | 0 |
| Parenchymal lung abnormalities | 8 | 0 | 8 | 8 | 6 |
| Retained primary teeth | 1 | 0 | 2 | 2 | 0 |
| Scoliosis | 0 | 0 | 0 | 0 | 0 |
| Fractures with minor trauma | 8 | 0 | 0 | 0 | 4 |
| Highest eosinophil count | 6 | 6 | 0 | 6 | 0 |
| Characteristic face | 5 | 2 | 0 | 5 | 0 |
| Midline anomaly | 0 | 0 | 0 | 0 | 0 |
| Newborn rash | 4 | 0 | 4 | 4 | 0 |
| Eczema | 4 | 2 | 1 | 0 | 0 |
| URTI/year | 4 | 4 | 0 | 0 | 0 |
| Candidiasis | 1 | 1 | 0 | 0 | 0 |
| Other serious infections | 0 | 4 | 0 | 4 | 0 |
| Fatal infections | 0 | 0 | 0 | 4 | 0 |
| Hyperextensibility | 0 | 0 | 4 | 0 | 0 |
| Lymphoma | 0 | 0 | 0 | 0 | 0 |
| Increased nasal width | 1 | 0 | 0 | 0 | 0 |
| High palate | 2 | 0 | 0 | 2 | 0 |
| Young age correction | |||||
| Total | 70 | 29 | 37 | 59 | 28 |
| STAT3 mutation | Yes | Yes | Yes | Yes | Yes |
Laboratory Investigations
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Eosinophil count (normal < 450/µl) | 250 | 1000 | 500 | 8650 | 0 |
| Serum IgE level IU/ml | > 2000 (normal 2–629) | > 2000 (normal 2–307) | > 2000 (normal 2–696) | > 2000 (normal 2–403) | > 2000 (normal 2–696) |
| Serum immunoglobulins (mg/dl) | |||||
| IgG (range) | >1120 (726–1085) | 1120 (569–1597) | 1098 (559–1492) | 1212 (559–1492) | 985 (779–1456) |
| IgA (range) | 40 (70–229) | 57 (55–152) | 153 (54–221) | 161 (54–221) | 44 (2–208) |
| IgM (range) | > 94.8 (35–72) | > 94.8 (22–100) | 264 (27–118) | 42 (27–118) | >94.8 (35–132) |
| Isohemagglutinin titre (normal > 1: 10 dilution) | Normal | Normal | Normal | Normal | Normal |
| Typhoid Vi IgG EU/Ml (Sero-positive ≥ 150 EU/ml) | > 600 | Not done | 503 | Not done | 312 |
| Lymphocyte subsets (/µl) | |||||
| CD 3 (normal range) | 12,920 (2300–6500) | ||||
| CD 4 (normal range) | 42% = 1290 (400–2100) | 32% = 1760 (300–2000) | 34% = 1478 (9300–2000) | 4718 (1500–5000) | 36% = 971 (400–2100) |
| CD 8 (normal range) | 35% = 1075 (200–1200) | 36% = 1980 (300–1800) | 31% = 1341 (399–1200) | 7461 (500–1600) | 27% = 749 (200–1200) |
| CD 19 (normal range) | 13% 399 (200–600) | 20% = 1100 (200–1600) | 23% = 995 (200–1600) | 4125 (600–3000) | 13% = 361 (200–600) |
| Mutation analysis of STAT3 gene | A heterozygous mutation in 1145 G to A in exon 13 leading to an amino acid change R382Q in the DNA binding domain | A heterozygous mutation in 1145 G to A in exon 13 leading to an amino acid change R382Q in the DNA binding domain | A heterozygous mutation in 1909 G to A in exon 21 leading to an amino acid change V637M in the SH2 domain | A heterozygous mutation in 1144 C to T in exon 13 leading to an amino acid change R382W in the DNA binding domain | A heterozygous mutation in 1909 G to A in exon 21 leading to an amino acid change V637M in the SH2 domain |
Comparison of US, European and Asian patients with STAT3 mutations positive AD-HIGE
| Clinical feature | US (n = 64) [ | French (n = 60) [ | Indian (n = 04) [ | Ethnic Chinese (n = 12) [ | Japanese (n = 08) [ | Sri Lankan (n = 05) |
|---|---|---|---|---|---|---|
| Age range | 1 month–46 years | 4 months–35 years | 1.7–26 years | 6–21 years | 5–15 years | |
| % | % | % | % (n) | % (n) | % | |
| Findings related to infections and immune system | ||||||
| Moderate to severe eczema | 90.6 | nm | nm | 91.6 (11/12) | 87.5 (7/8) | 60 |
| Serum IgE > 2000 IU/ml | nm | 96 | 100 | 75 (9/12) | 100 (8/8) | 100 |
| Eosinophilia (> 2 SD above normal mean) | 70.7 | 80 | 75 | 91.6 (11/12) | 75 (6/8) | 60 |
| Recurrent pneumonia, X-ray proven | 95 | nm | 50 | 75 (9/12) | 87.5 (7/8) | 40 |
| Recurrent skin abscesses | 90.6 | nm | 50 | 100 (12/12) | 75 (6/8, 2 = 1–2 abscesses) | 80 |
| Recurrent (> 3/year) upper respiratory infections | 45.8 | nm | nm | 71.4 (7/14) | 37.5 (3/8) | 80 |
| Mucocutaneous candidiasis | 43.1 | 85 | nm | 58.3 (7/12) | 67.5 (5/8) | 40 |
| Pneumatoceles | 74.6 | 52 | 25 | 66.6 (8/12) | 67.5 (5/8) | 60 |
| Newborn rash | 64.9 | 48 | 50 | 66.6 (8/12) | 100 (8/8) | 60 |
| Other serious infections | nm | 43 | 0 | 66.6 (8/12) | 25 (2/8) | 40 |
| Lymphoma, other cancer | 03 | 7 | 0 | 0 | 0 | 0 |
| Findings related to bones, teeth, and connective tissue | ||||||
| Characteristic face | 90.6 | 95 | 75 | 91.6 (11/12) | 100 (8/8) | 60 |
| Retained primary teeth | 80 | 65 | nm | 100 (5/5) | 37.5 (3/8) | 60 |
| Hyperextensibility of joints | 52.7 | 50 | nm | 58.3 (7/12) | 50 (4/8) | 20 |
| Increased nasal width (interalar distance > 1 SD above normal value for age, race) | 51.9 | 85 | nm | 80 (4/5) | 12.5 (1/8) | 20 |
| Scoliosis > 10° | 26 | 38 | nm | 0 | 25 (2/8) | 60 |
| Recurrent fractures following minor trauma | 45.8 | 42 | nm | 8.3 (1/12) | 25 (2/8) | 40 |
| High-arched palate | 54.7 | 53 | nm | 33.3 (3/12) | 25 (2/8) | 40 |
| Congenital skeletal anomalies | nm 10 | nm | nm | 0 | nm | 0 |
| Focal hyperintensities on brain MRI | nm | < 1 | nm | nm | nm | ne |
| Chiari type I malformation | nm | nm | nm | nm | nm | ne |
| Coronary vasculature abnormalities | nm | nm | nm | nm | nm | ne |
nm not mentioned, ne not evaluated
Fig. 3Schematic structure of STAT3. Previously described mutations [7] are shown in the upper part of the figure. Patients identified in this study with the STAT3 mutation (and number) are shown in the lower part of the figure
Clinical features
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Age at diagnosis and sex | 15 years, male | 5 years, female | 9 years, female | 7 years, female | 11 years, male |
| Age at onset | Neonatal period | 2 months | Neonatal period | Neonatal period | 4 months |
| Neonatal skin rash | Yes | No | Yes | Yes | No |
| Dermatitis | Yes | Yes | Yes | Yes | Yes |
| Candidiasis | Oral | Oral | No | No | No |
| Respiratory infections | Recurrent LRTI, pyo-pneumothorax at 3 months | Recurrent URTI, OM | Recurrent OM | Recurrent OM | Pyo-pneumothorax |
| Pneumatoceles | Yes | No | Yes | Multiple | No |
| Abscesses | Skin | No | Skin | Skin, peri-pancreatic | Skin, dento-alveolar, lung |
| Meningitis | No | Yes, recurrent (11 months, 2 years) | No | No | No |
| Other infections | No | No | No | Pericardial effusion | No |
| Retained teeth | Yes | No | Yes | Yes | |
| Fractures | Bilateral radius and ulna | No | No | No | Right ulna |
LRTI lower respiratory infections, URTI upper respiratory infections, OM otitis media